The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Daniel Peter Petrylak
Research Funding - Progenics
Philip W. Kantoff
Research Funding - Progenics
Anthony E. Mega
Research Funding - Progenics
Nicholas J. Vogelzang
Research Funding - Progenics
Joe Stephenson
Research Funding - Progenics
Mark T. Fleming
Research Funding - Progenics
Nancy Stambler
Employment or Leadership Position - Progenics
Stock Ownership - Progenics
Michaela Petrini
Employment or Leadership Position - Progenics
Stock Ownership - Progenics
Kathleen Huang
Employment or Leadership Position - Progenics
Robert Joseph Israel
Employment or Leadership Position - Progenics
Stock Ownership - Progenics